Description du projet
Une solution qui change la donne et révolutionne les hépatopathies
Les hépatopathies chroniques sont depuis longtemps considérées comme des tueurs silencieux, passant inaperçues jusqu’à ce qu’elles atteignent des stades impossibles à traiter. Parmi ces affections, la stéatose hépatique non alcoolique et son sous-type, la stéatohépatite non alcoolique, sont les principaux responsables. En l’absence de traitement, ces affections peuvent évoluer vers une cirrhose et une insuffisance hépatique, ce qui constitue une crise sanitaire mondiale. Cependant, la méthode actuelle pour diagnostiquer et stadifier les hépatopathies, à savoir la biopsie du foie, est onéreuse, invasive et risquée. Le projet RADIcAL, financé par l’UE, devrait transformer le paysage du diagnostic des hépatopathies et du suivi des traitements. Plus précisément, il s’agira de tester un logiciel d’imagerie par résonance magnétique avancé, non invasif et quantitatif. Cet outil présente une précision diagnostique remarquable dans l’évaluation précoce des hépatopathies et peut être utilisé pour la stratification des patients.
Objectif
Chronic liver diseases are called 'silent killers', as clinical symptoms only surface at late stages of the disease, when it is not treatable. Non-alcoholic fatty liver disease (NAFLD), a condition defined by fat accumulation in the liver, and its sub-type non-alcoholic steatohepatitis (NASH) are the major forms of liver disease. Untreated NAFLD/NASH can lead to cirrhosis and to liver failure. 450 million people worldwide suffer from fatty liver disease, which carries several health risks, and causes a huge socio-economic burden. At present, the only way of diagnosing and staging disease is with liver biopsy, which is costly, invasive, and carries some risk. Thus, clinicians are reluctant to use it for people suspected of having NAFLD/NASH. In addition, invasive biopsy is not optimal for serial assessment (e.g. monitoring transplant population for signs of liver rejection). Therefore, there is a lack of an accurate and non-invasive method of assessing liver disease and enabling treatment monitoring.
Perspectum Diagnostics Ltd (PD) has developed LiverMultiScan, a novel, non-invasive, quantitative Magnetic Resonance Imaging software tool that displays high diagnostic accuracy for the early assessment of liver disease, and can be used for patient stratification. It has recently obtained regulatory clearance, but it requires additional clinical validation to assure its broad market acceptance and reimbursement. Thus, RADIcAL entails two clinical trials: a) a multi-centre randomised health economic study to validate the cost-effectiveness and added value of LiverMultiScan compared to the standard care pathway for chronic liver disease; and (b) a prospective clinical trial to demonstrate the high sensitivity and specificity of LiverMultiScan as a medical support tool for stratifying patients at high risk of liver transplant rejection.
Champ scientifique
- medical and health sciencesclinical medicinesurgery
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesclinical medicinehepatology
- engineering and technologymedical engineeringdiagnostic imagingmagnetic resonance imaging
- medical and health scienceshealth sciencesnutritionobesity
Programme(s)
Thème(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
OX4 2LL Oxford
Royaume-Uni
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.